Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Wound
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Oxidopamine; 6-hydroxydopamine; 6-OHDA
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseWoundC57BL/6J and a knock-in Cys to Ala gene-mutated line on C57BL/6J backgroundFemale6-hydroxydopamine and SB 225002 intraperitoneal; timolol, isoepinephrine, tamsulosin and antibodies topical to the eye6-hydroxydopamine 100 mg/kg; timolol 5 microlitres of 0.01…6-hydroxydopamine on days -7, -5 and -3 before abrasion; adrenergic drugs appli…
Model: Central corneal epithelial abrasion (2 mm diameter marked with a trephine and scraped with a microspud) combined with acute tobacco smoke exposure (approximately 3 cigarettes over 90 min in a ventilated chamber)
Acute tobacco smoke exposure delayed corneal re-epithelialisation and amplified neutrophil and gamma delta T cell influx with raised NF-kappaB, IL-6 and IL-17 expression, and sympathectomy, adrenergic receptor blockade and IL-6 or IL-17A neutralisation each independently attenuated these effects.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.